A group of six senators has written to recently-appointed US Patent and Trademark Office director Kathi Vidal, imploring her office to address the impact of so-called patent thickets on generic and biosimilar drug competition.
Developers of originator drugs are known to take out large numbers of patents to cover a single product or minor variations upon it, such as tweaks to delivery mechanisms, dosages or formulations. This practice,
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?